Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Magnesium Supplementation in Addition to Standard Chemo-immunotherapy in Patients With Locally Advanced Unresectable Stage III or Metastatic Stage IV Non-small Cell Lung Cancer (NSCLC). A Double-blind Randomized Multicenter Phase II/III Study.

NCT07149649 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT07149649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07149649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Magnesium Supplementation in Addition to Standard Chemo-immunotherapy in Patients With Locally Advanced Unresectable Stage III or Metastatic Stage IV Non-small Cell Lung Cancer (NSCLC). A Double-blind Randomized Multicenter Phase II/III Study.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
March 31, 2035
Enrollment
230 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nsclc - non-small cell lung cancer